INTS
Intensity Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.01
+0.25%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 14.0K | 26.0K | — | 147.0K | — |
| Gross Profit | (14.0K) | (26.0K) | — | (147.0K) | — |
| Operating Expenses | |||||
| R&D Expense | 6.1M | 6.8M | 10.5M | 4.8M | 5.1M |
| SG&A Expense | 5.4M | 5.2M | 6.1M | 3.4M | 2.4M |
| General & Admin Expense | 5.4M | 5.2M | 6.1M | 3.5M | 2.4M |
| Selling & Marketing Expense | — | — | — | (147.0K) | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 11.5M | 12.0M | 16.6M | 8.2M | 7.5M |
| Cost and Expenses | 11.5M | 12.0M | 16.6M | 8.3M | 7.5M |
| Operating Income (EBIT) | (11.5M) | (12.0M) | (16.6M) | (8.3M) | (7.5M) |
| Non-Operating | |||||
| Interest Income | 318.0K | 180.0K | 314.0K | 324.0K | 2.5K |
| Interest Expense | — | — | — | 305.0K | 81.8K |
| Net Interest Income | 318.0K | 180.0K | 314.0K | 19.0K | (79.3K) |
| Other Non-Op Income/Expense | 320.0K | 366.0K | 317.0K | (2.2M) | (32.0K) |
| Non-Operating Income (excl Interest) | (243.0K) | (366.0K) | (317.0K) | 1.9M | (50.0K) |
| EBT (Pre-Tax Income) | (11.2M) | (11.6M) | (16.3M) | (10.5M) | (7.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (11.2M) | (11.6M) | (16.3M) | (10.5M) | (7.6M) |
| Earnings from Cont. Ops | (11.2M) | (11.6M) | (16.3M) | (10.5M) | (7.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (11.2M) | (11.6M) | (16.3M) | (11.9M) | (7.6M) |
| Per Share | |||||
| Basic EPS | ($4.83) | ($8.56) | ($29.25) | ($34.50) | ($55.50) |
| Diluted EPS | ($4.83) | ($8.56) | ($29.25) | ($34.50) | ($55.50) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 27.1M | 13.6M | 556240 | 306160 | 136400 |
| Diluted Shares Outstanding | 27.1M | 13.6M | 556279 | 344653 | 136404 |
| Profitability Metrics | |||||
| EBITDA | (8.5M) | (11.6M) | (16.3M) | (10.1M) | (7.3M) |
| D&A | 2.7M | — | — | 147.0K | 179.0K |
| EBIT | (11.2M) | (11.6M) | (16.3M) | (10.2M) | (7.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026